中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 5
May  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(5): 1004-1009

Clinical research advances in mesenchymal stem cells for the treatment of autoimmune liver diseases

DOI: 10.3969/j.issn.1001-5256.2023.05.002

  • Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China

More Information
  • Corresponding author: WANG Guiqiang, john131212@sina.com (ORCID: 0000-0003-0515-7974)
  • Received Date: 2023-03-14
  • Accepted Date: 2023-04-11
  • Published Date: 2023-05-20
    Abstract
  • Due to limited options and modalities for the etiological treatment of autoimmune liver diseases, it is urgent to seek new therapeutic methods for liver autoimmune diseases. As the most common source of cells for stem cell therapy, mesenchymal stem cells (MSCs) play an important role in regulating innate and adaptive immune responses and have been widely used in clinical trials for the treatment of autoimmune diseases and inflammatory diseases. Recent experimental and clinical studies have shown that MSCs and MSC-EVs can inhibit the activation and proliferation of a variety of liver proinflammatory cells (such as Th1, Th17, and M1 macrophages), regulate the differentiation of different subsets of T and B cells, reduce the secretion of proinflammatory cytokines, and promote the proliferation of anti-inflammatory cells, thereby playing an immunoregulatory role. This article reviews the clinical trials of MSCs and MSC-EVs in the treatment of autoimmune liver diseases and their mechanism in regulating immune function and promoting hepatocyte regeneration and briefly describes the potential application and limitations of MSCs and MSC-EVs in clinical practice.

     

    • FullText(HTML)
  • loading
    • References(54)
  • [1]
    RONCA V, MANCUSO C, MILANI C, et al. Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis[J]. J Leukoc Biol, 2020, 108(2): 659-671. DOI: 10.1002/JLB.5MR0320-200R.
    [2]
    LONGHI MS. Lactobacillus reuteri joins the liver autoimmune arena[J]. Cell Host Microbe, 2022, 30(7): 901-903. DOI: 10.1016/j.chom.2022.06.004.
    [3]
    GULAMHUSEIN AF, HIRSCHFIELD GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2): 93-110. DOI: 10.1038/s41575-019-0226-7.
    [4]
    LEE CW, CHEN YF, WU HH, et al. Historical perspectives and advances in mesenchymal stem cell research for the treatment of liver diseases[J]. Gastroenterology, 2018, 154(1): 46-56. DOI: 10.1053/j.gastro.2017.09.049.
    [5]
    FRIEDENSTEIN AJ, PETRAKOVA KV, KUROLESOVA AI, et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues[J]. Transplantation, 1968, 6(2): 230-247.
    [6]
    HASHMI S, AHMED M, MURAD MH, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis[J]. Lancet Haematol, 2016, 3(1): e45-52. DOI: 10.1016/S2352-3026(15)00224-0.
    [7]
    FUJⅡ S, MIURA Y. Immunomodulatory and regenerative effects of MSC-derived extracellular vesicles to treat acute GVHD[J]. Stem Cells, 2022, 40(11): 977-990. DOI: 10.1093/stmcls/sxac057.
    [8]
    WONG SK, BLUM SM, SUN X, et al. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma[J]. Eur J Cancer, 2023, 181: 188-197. DOI: 10.1016/j.ejca.2022.12.013.
    [9]
    LEE E, EPANOMERITAKIS IE, LU V, et al. Bone marrow-derived mesenchymal stem cell implants for the treatment of focal chondral defects of the knee in animal models: a systematic review and meta-analysis[J]. Int J Mol Sci, 2023, 24(4) : 3227. DOI: 10.3390/ijms24043227.
    [10]
    DU F, LIU M, WANG J, et al. Metformin coordinates with mesenchymal cells to promote VEGF-mediated angiogenesis in diabetic wound healing through Akt/mTOR activation[J]. Metabolism, 2023, 140: 155398. DOI: 10.1016/j.metabol.2023.155398.
    [11]
    QIN L, LIU N, BAO CL, et al. Mesenchymal stem cells in fibrotic diseases-the two sides of the same coin[J]. Acta Pharmacol Sin, 2023, 44(2): 268-287. DOI: 10.1038/s41401-022-00952-0.
    [12]
    KERKAR N, CHAN A. Autoimmune hepatitis, sclerosing cholangitis, and autoimmune sclerosing cholangitis or o verlap syndrome[J]. Clin Liver Dis, 2018, 22(4): 689-702. DOI: 10.1016/j.cld.2018.06.005.
    [13]
    LIBERAL R, GRANT CR, LONGHI MS, et al. Diagnostic criteria of autoimmune hepatitis[J]. Autoimmun Rev, 2014, 13(4-5): 435-440. DOI: 10.1016/j.autrev.2013.11.009.
    [14]
    TRIVEDI PJ, HUBSCHER SG, HENEGHAN M, et al. Grand round: Autoimmune hepatitis[J]. J Hepatol, 2019, 70(4): 773-784. DOI: 10.1016/j.jhep.2018.11.006.
    [15]
    L VOLK M, REAU N. Diagnosis and management of autoimmune hepatitis in adults and children: a patient-friendly summary of the 2019 AASLD guidelines[J]. Clin Liver Dis (Hoboken), 2021, 17(2): 85-89. DOI: 10.1002/cld.1080.
    [16]
    LOHSE AW, SEBODE M, JØRGENSEN MH, et al. Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group[J]. J Hepatol, 2020, 73(6): 1496-1506. DOI: 10.1016/j.jhep.2020.07.023.
    [17]
    HORWICH BH, HAN H. Diagnosis and treatment of primary biliary cholangitis: A patient-friendly summary of the 2018 AASLD practice guidance[J]. Clin Liver Dis (Hoboken), 2021, 18(5): 255-259. DOI: 10.1002/cld.1158.
    [18]
    SHAH RA, KOWDLEY KV. Current and potential treatments for primary biliary cholangitis[J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 306-315. DOI: 10.1016/S2468-1253(19)30343-7.
    [19]
    WANG L, LI J, LIU H, et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis[J]. J Gastroenterol Hepatol, 2013, 28 Suppl 1: 85-92. DOI: 10.1111/jgh.12029.
    [20]
    WANG L, HAN Q, CHEN H, et al. Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis[J]. Stem Cells Dev, 2014, 23(20): 2482-2489. DOI: 10.1089/scd.2013.0500.
    [21]
    LINDKVIST B, BENITO DE VALLE M, GULLBERG B, et al. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden[J]. Hepatology, 2010, 52(2): 571-577. DOI: 10.1002/hep.23678.
    [22]
    MODHA K, NAVANEETHAN U. Diagnosis and management of primary sclerosing cholangitis-perspectives from a therapeutic endoscopist[J]. World J Hepatol, 2015, 7(5): 799-805. DOI: 10.4254/wjh.v7.i5.799.
    [23]
    JADLOWIEC CC, TANER T. Liver transplantation: Current status and challenges[J]. World J Gastroenterol, 2016, 22(18): 4438-4445. DOI: 10.3748/wjg.v22.i18.4438.
    [24]
    HU C, ZHAO L, DUAN J, et al. Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis[J]. J Cell Mol Med, 2019, 23(3): 1657-1670. DOI: 10.1111/jcmm.14115.
    [25]
    RAPOSO G, STOORVOGEL W. Extracellular vesicles: exosomes, microvesicles, and friends[J]. J Cell Biol, 2013, 200(4): 373-383. DOI: 10.1083/jcb.201211138.
    [26]
    HE C, YANG Y, ZHENG K, et al. Mesenchymal stem cell-based treatment in autoimmune liver diseases: underlying roles, advantages and challenges[J]. Ther Adv Chronic Dis, 2021, 12: 2040622321993442. DOI: 10.1177/2040622321993442.
    [27]
    LO SICCO C, REVERBERI D, BALBI C, et al. Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization[J]. Stem Cells Transl Med, 2017, 6(3): 1018-1028. DOI: 10.1002/sctm.16-0363.
    [28]
    DUFFY MM, RITTER T, CEREDIG R, et al. Mesenchymal stem cell effects on T-cell effector pathways[J]. Stem Cell Res Ther, 2011, 2(4): 34. DOI: 10.1186/scrt75.
    [29]
    KHARE D, OR R, RESNICK I, et al. Mesenchymal stromal cell-derived exosomes affect mrna expression and function of B-lymphocytes[J]. Front Immunol, 2018, 9: 3053. DOI: 10.3389/fimmu.2018.03053.
    [30]
    SU J, CHEN X, HUANG Y, et al. Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species[J]. Cell Death Differ, 2014, 21(3): 388-396. DOI: 10.1038/cdd.2013.149.
    [31]
    CHABANNES D, HILL M, MERIEAU E, et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells[J]. Blood, 2007, 110(10): 3691-3694. DOI: 10.1182/blood-2007-02-075481.
    [32]
    NÉMETH K, LEELAHAVANICHKUL A, YUEN PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production[J]. Nat Med, 2009, 15(1): 42-49. DOI: 10.1038/nm.1905.
    [33]
    CHEN D, TANG P, LIU L, et al. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway[J]. Cell Cycle, 2018, 17(7): 858-867. DOI: 10.1080/15384101.2018.1442624.
    [34]
    SIOUD M, MOBERGSLIEN A, BOUDABOUS A, et al. Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation[J]. Scand J Immunol, 2010, 71(4): 267-274. DOI: 10.1111/j.1365-3083.2010.02378.x.
    [35]
    CHEN QH, WU F, LIU L, et al. Mesenchymal stem cells regulate the Th17/Treg cell balance partly through hepatocyte growth factor in vitro[J]. Stem Cell Res Ther, 2020, 11(1): 91. DOI: 10.1186/s13287-020-01612-y.
    [36]
    DUNN CM, KAMEISHI S, CHO YK, et al. Interferon-gamma primed human clonal mesenchymal stromal cell sheets exhibit enhanced immunosuppressive function[J]. Cells, 2022, 11(23): e202301924. DOI: 10.3390/cells11233738.
    [37]
    LI M, SUN X, KUANG X, et al. Mesenchymal stem cells suppress CD8+ T cell-mediated activation by suppressing natural killer group 2, member D protein receptor expression and secretion of prostaglandin E2, indoleamine 2, 3-dioxygenase and transforming growth factor-β[J]. Clin Exp Immunol, 2014, 178(3): 516-524. DOI: 10.1111/cei.12423.
    [38]
    AKIYAMA K, CHEN C, WANG D, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis[J]. Cell Stem Cell, 2012, 10(5): 544-555. DOI: 10.1016/j.stem.2012.03.007.
    [39]
    LUZ-CRAWFORD P, KURTE M, BRAVO-ALEGRÍA J, et al. Mesenchymal stem cells generate a CD4+CD25+ Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells[J]. Stem Cell Res Ther, 2013, 4(3): 65. DOI: 10.1186/scrt216.
    [40]
    LIM VY, FENG X, MIAO R, et al. Mature B cells and mesenchymal stem cells control emergency myelopoiesis[J]. Life Sci Alliance, 2023, 6(4): e202301924. DOI: 10.26508/lsa.202301924.
    [41]
    GARCIA SG, SANDOVAL-HELLÍN N, CLOS-SANSALVADOR M, et al. Mesenchymal stromal cells induced regulatory B cells are enriched in extracellular matrix genes and IL-10 independent modulators[J]. Front Immunol, 2022, 13: 957797. DOI: 10.3389/fimmu.2022.957797.
    [42]
    RAFEI M, HSIEH J, FORTIER S, et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction[J]. Blood, 2008, 112(13): 4991-4998. DOI: 10.1182/blood-2008-07-166892.
    [43]
    FRANQUESA M, MENSAH FK, HUIZINGA R, et al. Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells[J]. Stem Cells, 2015, 33(3): 880-891. DOI: 10.1002/stem.1881.
    [44]
    TAMURA R, UEMOTO S, TABATA Y. Immunosuppressive effect of mesenchymal stem cell-derived exosomes on a concanavalin A-induced liver injury model[J]. Inflamm Regen, 2016, 36: 26. DOI: 10.1186/s41232-016-0030-5.
    [45]
    LU FB, CHEN DZ, CHEN L, et al. Attenuation of experimental autoimmune hepatitis in mice with bone mesenchymal stem cell-derived exosomes carrying MicroRNA-223-3p[J]. Mol Cells, 2019, 42(12): 906-918. DOI: 10.14348/molcells.2019.2283.
    [46]
    CHEN L, LU FB, CHEN DZ, et al. BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis[J]. Mol Immunol, 2018, 93: 38-46. DOI: 10.1016/j.molimm.2017.11.008.
    [47]
    SHAO Y, YANG WY, SAAOUD F, et al. IL-35 promotes CD4+Foxp3+ Tregs and inhibits atherosclerosis via maintaining CCR5-amplified Treg-suppressive mechanisms[J]. JCI Insight, 2021, 6(19): e152511. DOI: 10.1172/jci.insight.152511.
    [48]
    WANG W, GUO H, LI H, et al. Interleukin-35 gene- modified mesenchymal stem cells protect concanavalin a-induced fulminant hepatitis by decreasing the interferon gamma level[J]. Hum Gene Ther, 2018, 29(2): 234-241. DOI: 10.1089/hum.2017.171.
    [49]
    WANG D, ZHANG H, LIANG J, et al. Effect of allogeneic bone marrow-derived mesenchymal stem cells transplantation in a polyI: C-induced primary biliary cirrhosis mouse model[J]. Clin Exp Med, 2011, 11(1): 25-32. DOI: 10.1007/s10238-010-0105-6.
    [50]
    ZHANG L, MA XJ, FEI YY, et al. Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells[J]. Pharmacol Ther, 2022, 232: 108004. DOI: 10.1016/j.pharmthera.2021.108004.
    [51]
    NIE H, AN F, MEI J, et al. IL-1β Pretreatment improves the efficacy of mesenchymal stem cells on acute liver failure by enhancing CXCR4 Expression[J]. Stem Cells Int, 2020, 2020: 1498315. DOI: 10.1155/2020/1498315.
    [52]
    ZHAO Q, REN H, LI X, et al. Differentiation of human umbilical cord mesenchymal stromal cells into low immunogenic hepatocyte-like cells[J]. Cytotherapy, 2009, 11(4): 414-426. DOI: 10.1080/14653240902849754.
    [53]
    HONCZARENKO M, LE Y, SWIERKOWSKI M, et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors[J]. Stem Cells, 2006, 24(4): 1030-1041. DOI: 10.1634/stemcells.2005-0319.
    [54]
    WANG J, SUN M, LIU W, et al. Stem cell-based therapies for liver diseases: An overview and update[J]. Tissue Eng Regen Med, 2019, 16(2): 107-118. DOI: 10.1007/s13770-019-00178-y.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (691) PDF downloads(155) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return